ArticleCancer discovery2017
Immune Escape in Breast Cancer During
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 181 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
181citing papers in PubMed, 2 pooled it
9.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
181 citing papers in PubMed, 2 syntheses or guidelines pooled it, 239 citations in OpenAlex.
- Pooled it
- CTLA-4 Expression and Its Clinical Significance in Breast Cancer.Archivum immunologiae et therapiae experimentalis · 2021Pooled it
- Tumoral pSMAD2 as a prognostic biomarker in early-stage breast cancer: insights from the randomized SweBCG91RT trial.Breast cancer research and treatment · 2025Trial
- DHX15 as a novel immune-related prognostic biomarker in breast cancer: An integrated bioinformatics analysis withOncology letters · 2026Article
- Breast cancer prevention by prophylactic Lalba mRNA-LNP vaccination.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- A Small Natural Molecule Targeting IL-23/IL-17 Axis Exerts Dual Effects on T-Cell Function and Breast Cancer Cell Migration.Medical sciences (Basel, Switzerland) · 2026Article
- Tumor evolution: signaling pathways, molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Integrative machine learning reveals a TLS signature and CCL5-CCR1 axis-associated immune remodeling in breast cancer.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Immunohistochemical characterization of the tumor immune microenvironment in laryngeal premalignancy: insights into early immune alterations in carcinogenesis.Virchows Archiv : an international journal of pathology · 2026Article
- Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression.Cancer cell · 2026Article
- Racial Disparity in Ductal Carcinoma in Situ: Risk-Predictive and Actionable Biomarkers for Early Intervention.Cancers · 2026Review
- Distinct genomic and immunologic tumor evolution in germline TP53-driven breast cancers.Nature communications · 2026Article
- T-helper Transcription Factor Profiling in Peripheral Blood Mononuclear Cells: A Non-invasive Approach to Predicting Disease Stage in Breast Cancer.Biochemical genetics · 2026Article
- Evaluation of targeted and immune combination therapies in a rat model of hormone receptor-positive breast cancer.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- The impact of immune microenvironment on local control of ductal carcinoma in situ receiving breast conservative therapy.Breast cancer research : BCR · 2026Article
- CRISPR screens identify PRMT7 as a therapeutic target to enhance T cell-mediated killing in breast cancer.NPJ breast cancer · 2026Article
- Preclinical ex vivo and in vivo models to study immunotherapy agents and their combinations as predictive tools toward the clinic.Journal for immunotherapy of cancer · 2025Review
- Roles of Neutrophils in Autoimmune Diseases and Cancers.International journal of molecular sciences · 2025Review
- Single-cell multi-omics in cancer immunotherapy: from tumor heterogeneity to personalized precision treatment.Molecular cancer · 2025Review
- Spatial proteomics and transcriptomics reveal early immune cell organization in pancreatic intraepithelial neoplasia.JCI insight · 2025Article
121 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
30 authors at 3 institutions in 1 country.
Carlos R Gil Del AlcazarDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Sung Jin HuhDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Muhammad B EkramDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Anne TrinhDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Lin L LiuDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Francisco BecaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Xiaoyuan ZiDepartment of Biomedical Engineering, Yale University, New Haven, Connecticut.
Minsuk KwakDepartment of Biomedical Engineering, Yale University, New Haven, Connecticut.
Helga BergholtzDepartment of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Ying SuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Lina DingDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Hege G RussnesDepartment of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Andrea L RichardsonDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Kirsten BabskiSutter Roseville Medical Center, Roseville, California.
Elizabeth Min Hui KimSutter Roseville Medical Center, Roseville, California.
Charles H McDonnellSutter Roseville Medical Center, Roseville, California.
Jon WagnerSutter Roseville Medical Center, Roseville, California.
Ron RowberrySutter Roseville Medical Center, Roseville, California.
Gordon J FreemanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Deborah DillonDepartment of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
Therese SorlieDepartment of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Lisa M CoussensDepartment of Cell, Developmental & Cancer Biology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon.
Judy E GarberDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Rong FanDepartment of Biomedical Engineering, Yale University, New Haven, Connecticut.
Kristie BobolisSutter Roseville Medical Center, Roseville, California.
D Craig AllredDepartment of Pathology, Washington University School of Medicine, St. Louis, Missouri.
Joon JeongDepartment of Surgery, Gangnam Severance Hospital, Yonsei University Medical College, Seoul, Korea.
So Yeon ParkDepartment of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Franziska MichorDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Kornelia PolyakDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. kornelia_polyak@dfci.harvard.edu.
Brigham and Women's Hospital · USHarvard University · USDana-Farber Cancer Institute · US
Funding
Targeting intratumor heterogeneity in breast cancerR35CA197623 · NCI · DANA-FARBER CANCER INST · PI KORNELIA POLYAK · 2015 to 2026
$12.4MProject 3: Single Cell Measures of Intratumor Diversity for Optimal Breast Cancer TherapyU54CA193461 · NCI · DANA-FARBER CANCER INST · PI MICHOR, FRANZISKA · 2015 to 2020
$11.2MThe Role of Immune Cells in Breast Development and CancerF32CA156991 · NCI · DANA-FARBER CANCER INST · PI HUH, SUNG JIN · 2011 to 2013
$161kNCI NIH HHS F32 CA156991NCI NIH HHS R35 CA197623NCI NIH HHS U54 CA193461
Abstract
To investigate immune escape during breast tumor progression, we analyzed the composition of leukocytes in normal breast tissues, ductal carcinoma
Indexed as
B7-H1 AntigenBiomarkers, TumorBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingCD3 ComplexDisease ProgressionErb-b2 Receptor Tyrosine KinasesFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLeukocyte Common AntigensT-LymphocytesTumor MicroenvironmentB7-H1 AntigenBiomarkers, TumorCD274 protein, humanCD3 ComplexErb-b2 Receptor Tyrosine KinasesLeukocyte Common AntigensPTPRC protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.